<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00275457</url>
  </required_header>
  <id_info>
    <org_study_id>248.520</org_study_id>
    <nct_id>NCT00275457</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks Followed by 46 Weeks Open-label or Double-blind Treatment Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from&#xD;
      moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 week&#xD;
      open label or double blind extension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from&#xD;
      moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 weeks&#xD;
      open label or double blind extension&#xD;
&#xD;
      Study Hypotheses:&#xD;
&#xD;
      Null hypothesis: No difference between pramipexole and placebo in RLSRS total score from&#xD;
      baseline and no difference in the CGI-I responder rates at the end of the 6 weeks&#xD;
      double-blind treatment.&#xD;
&#xD;
      Comparison(s):&#xD;
&#xD;
      Pramipexole vs. Placebo&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date>April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline to week 6 on the RLSRS +</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>CGI-I responders (much and very much improved)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>RLRS responders, CGI, PGI responders, EPSS, QoL (SF-36) VAS severity of RLS</measure>
  </secondary_outcome>
  <enrollment>346</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Male or female out-patients aged 18-80&#xD;
&#xD;
          2. Diagnosis of idiopathic RLS according to the Clinical RLS criteria of the&#xD;
             International RLS Study Group. All of the four criteria must be present:&#xD;
&#xD;
               -  Irresistible urge to move usually associated with sensory complaints of the lower&#xD;
                  limbs&#xD;
&#xD;
               -  Motor restlessness&#xD;
&#xD;
               -  Worsening of the symptoms at rest with at least partial and temporary relief by&#xD;
                  activity&#xD;
&#xD;
               -  Increased severity in the evening or at night&#xD;
&#xD;
          3. RLS rating scale for severity score &gt; 15&#xD;
&#xD;
          4. RLS symptoms present at least 2 to 3 days per week within in the last 3 months&#xD;
&#xD;
          5. Written informed consent consistent with ICH/GCP and local legislation given prior to&#xD;
             any study procedures&#xD;
&#xD;
          6. Ability and willingness to comply with study treatment regimen and to attend study&#xD;
             assessments&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Women of childbearing potential, who do not use adequate protection such as barrier&#xD;
             protection, intrauterine device, or hormonal (oral or subcutaneous) contraception or&#xD;
             postmenopausal women less than 6 months after last menses, surgically sterilised,&#xD;
             oophorectomised or hysterectomised less than 3 months after operation and not using&#xD;
             adequate protection or women neither using adequate protection nor being&#xD;
             postmenopausal and their partner is not sterilised at least 6 months post operation or&#xD;
             does not use condom, or any women not having negative serum pregnancy test at&#xD;
             screening&#xD;
&#xD;
          2. Males not using an adequate form of contraception (condom, sterilisation at least 6&#xD;
             months post operation)&#xD;
&#xD;
          3. Patients who are breastfeeding&#xD;
&#xD;
          4. Concomitant or previous pharmacologically therapy of RLS as follows:&#xD;
&#xD;
               -  Any intake of levodopa within 5 days prior to baseline visit (V2)&#xD;
&#xD;
               -  Any intake of dopamine agonists within 14 days prior to baseline visit (V2)&#xD;
&#xD;
               -  History of any intake of pramipexole&#xD;
&#xD;
          5. Current (less than 14 days before treatment with trial medication or concomitant)&#xD;
             treatment with medication or dietary supplements, which could significantly influence&#xD;
             RLS symptoms - withdrawal symptoms caused by stopping any of the drugs above&#xD;
&#xD;
          6. Confirmed diagnose of diabetes mellitus requiring insulin therapy&#xD;
&#xD;
          7. Clinically significant renal disease or creatinine higher than upper limit of normal&#xD;
             (ULN) at screening&#xD;
&#xD;
          8. Clinically significant hepatic disease or sGPT &gt; 2 times the upper limit of normal&#xD;
             range at screening&#xD;
&#xD;
          9. Clinical or laboratory signs of microcytic anaemia at the investigators discretion&#xD;
&#xD;
         10. Any of the following lab results at screening:&#xD;
&#xD;
               -  Hb or erythrocyte count below lower limit of normal (LLN)&#xD;
&#xD;
               -  Basal TSH, T3 or T4 clinically significantly (at the investigator's discretion)&#xD;
                  out of normal range at screening (if not caused by substitution therapy according&#xD;
                  the investigator's opinion)&#xD;
&#xD;
         11. Other clinically significant metabolic-endocrine, haematological, gastro-intestinal&#xD;
             disease or pulmonary disease. Poorly controlled cardiovascular disease&#xD;
&#xD;
         12. History or clinical signs of peripheral neuropathy (PNP) of any origin in physical,&#xD;
             neurological examination, myelopathy or multiple sclerosis or any other neurological&#xD;
             disease, with potential to secondarily cause RLS symptoms&#xD;
&#xD;
         13. Presence of any other sleep disorder, such as, REM sleep behaviour disorder,&#xD;
             narcolepsy or sleep apnoea syndrome&#xD;
&#xD;
         14. History of Schizophrenia or any psychotic disorder, history of mental disorders due to&#xD;
             a general medical condition or any present axis I psychiatric disorder according DSM&#xD;
             IV requiring any medical therapy or history of or alcohol abuse or drug addiction&#xD;
             within the last 2 years before screening&#xD;
&#xD;
         15. Participation in a drug study within two months prior to the start of this study&#xD;
&#xD;
         16. History of or clinical signs for any form of epilepsy or seizures apart from fever&#xD;
             related seizures in early childhood&#xD;
&#xD;
         17. History of or clinical signs of malign neoplasm&#xD;
&#xD;
         18. Patients on a shift-work-schedule, or who are otherwise unable to follow a regular&#xD;
             sleep-wake cycle enabling use of study medication at times indicated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>B.I. Pharma GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ.-Klinik für Neurologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.-Klinik für Neurologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Confraternität Privatklinik</name>
      <address>
        <city>Wien</city>
        <zip>1080</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Universitätsklinik für Psychiatrie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sonderkrankenanstalt für neurologischen und</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Dürrheim-Sunthausen</city>
        <zip>78073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Neurologie</name>
      <address>
        <city>Emmendingen</city>
        <zip>79312</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kehl</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH &amp; Co. KG</name>
      <address>
        <city>Leipzig</city>
        <zip>04229</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen und Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beek en Donk</city>
        <zip>5741 AR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2585 LJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deurne</city>
        <zip>5751 XJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ewijk</city>
        <zip>6644 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lichtenvoorde</city>
        <zip>7131 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rijswijk</city>
        <zip>2281 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roelofarendsveen</city>
        <zip>2371 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3082 DC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>N-2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>N-0159</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>N-0303</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tønsberg</city>
        <zip>N-3111</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stockholms Neuro Center</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologkliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Läkarhuset Vällingby</name>
      <address>
        <city>Vällingby</city>
        <zip>162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Västra Frölunda</city>
        <zip>421 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.520_U05-1394-01.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.520_literature.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>January 11, 2006</study_first_submitted>
  <study_first_submitted_qc>January 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2006</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

